EXUS as partner
Improving quality of life of advanced pancreatic cancer patients through an AI-guided multimodal intervention, combining pain and cachexia management, nutrition, and physical activity
RELEVIUM empowers patients and assists them in living a less strenuous life while they are forced to endure the difficulties of pancreatic cancer.
The main hypothesis of RELEVIUM is that quality of life (QoL) of advanced pancreatic cancer patients can be significantly improved by reducing pain and cachexia through highly personalised nutrition, physical activity, and pain management strategies, in addition to chemotherapy treatment. To achieve this, RELEVIUM will empower patients with digital tools that facilitate patient-doctor communication and enable them to self-manage their disease.
09/2022 - 08/2026
RELEVIUM will use (i) a multi-sensor smartwatch and an innovative remote ultrasound patch, (ii) AI algorithms for continuous remote monitoring of pain and sarcopenia, as well as for decision support, and (iii) patient and caregiver applications. Combined, these tools will provide a stream of evidence on symptom progression and will enable physicians to apply personalised care plans.
RELEVIUM brings together an interdisciplinary team of experts and will also involve patients and their caregivers in an iterative co-creation process. The project will initially conduct a feasibility and data collection study (RELEVIUM-FDC, n=130). The study aims at optimizing patient adherence and compliance, and at collecting data for the development of the intervention. A five-centre randomized clinical trial (RELEVIUM-RCT) will then evaluate the efficacy of the proposed personalised care plans for advanced pancreatic cancer patients (n=132) in terms of their QoL. Several secondary outcomes will be investigated, such as the cost-effectiveness of the intervention, its potential in increasing health equity and in relieving the stress burden on the patient families.
The study outcomes will result in recommendations for integrating remote monitoring and improving QoL outcomes in palliative care for advanced pancreatic cancer
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ (Germany)
JOHANNES GUTENBERG-UNIVERSITAT MAINZ (Germany)
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS (Greece)
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV (Germany)
CHAROKOPEIO PANEPISTIMIO (Greece)
EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINIS (Greece)
AINIGMA TECHNOLOGIES (Belgium)
MCS DATALABS (Germany)
FUTURO PERFECTO INNOVACION SL (Spain)
EUROPEAN CANCER PATIENT COALITION (Belgium)
INSTITUT CURIE (France)
THE HEALTH CORPORATION - RAMBAM (Israel)
SIHTASUTUS POHJA-EESTI REGIONAALHAIGLA (Estonia)
INSTITUT JULES BORDET ASBL (Belgium)
DBC EUROPE (Belgium)
PULSIFY MEDICAL BV (Belgium)
CSI CENTER FOR SOCIAL INNOVATION LTD (Cyprus)
ROZENBAUM KONSULTING (Bulgaria)